Thrombosis and a hypercoagulable state in HIV-infected patients

Yu Min P Shen, Eugene P. Frenkel

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Human immunodeficiency virus infection is an illness with protean manifestations including hematological abnormalities. Thromboembolic complications in HIV-infected patients have been described. Recent literature describes an incidence ranging from 0.26% to 7.6%; higher incidence is seen in patients with active opportunistic infections or malignancy, and in patients with the acquired immunodeficiency syndrome. A variety of potential mechanisms have been proposed to account for the observed hypercoagulability in HIV-infected patients. These include the presence of antiphospholipid- anticardiolipin antibodies, decreased activities of natural anticoagulants (especially protein S), and increased platelet activation. Recent epidemiological studies emphasize the increased incidence of thromboembolic events including myocardial infarction in the HIV-infected population after the introduction of highly active antiretroviral therapy. The use of protease inhibitors in particular is implicated. A hypercoagulable state and especially thromboses are emerging as clinical issues in HIV-infected patients. Further studies are in order to more clearly delineate the pathophysiologic mechanism(s) of thromboses in HIV-infected patients.

Original languageEnglish (US)
Pages (from-to)277-280
Number of pages4
JournalClinical and Applied Thrombosis/Hemostasis
Volume10
Issue number3
DOIs
StatePublished - Jul 2004

Fingerprint

Thrombosis
HIV
Incidence
Anticardiolipin Antibodies
Antiphospholipid Antibodies
Thrombophilia
Protein S
Opportunistic Infections
Highly Active Antiretroviral Therapy
Platelet Activation
Virus Diseases
Protease Inhibitors
Anticoagulants
Epidemiologic Studies
Acquired Immunodeficiency Syndrome
Myocardial Infarction
Population
Neoplasms

Keywords

  • Acquired immunodeficiency syndrome
  • Highly active antiretroviral therapy
  • Human immunodeficiency virus
  • Hypercoagulable state
  • Opportunistic infections
  • Platelet activation
  • Protease inhibitors
  • Protein S deficiency

ASJC Scopus subject areas

  • Hematology

Cite this

Thrombosis and a hypercoagulable state in HIV-infected patients. / Shen, Yu Min P; Frenkel, Eugene P.

In: Clinical and Applied Thrombosis/Hemostasis, Vol. 10, No. 3, 07.2004, p. 277-280.

Research output: Contribution to journalArticle

@article{b4a69d0d77fe4451908d6a8754940453,
title = "Thrombosis and a hypercoagulable state in HIV-infected patients",
abstract = "Human immunodeficiency virus infection is an illness with protean manifestations including hematological abnormalities. Thromboembolic complications in HIV-infected patients have been described. Recent literature describes an incidence ranging from 0.26{\%} to 7.6{\%}; higher incidence is seen in patients with active opportunistic infections or malignancy, and in patients with the acquired immunodeficiency syndrome. A variety of potential mechanisms have been proposed to account for the observed hypercoagulability in HIV-infected patients. These include the presence of antiphospholipid- anticardiolipin antibodies, decreased activities of natural anticoagulants (especially protein S), and increased platelet activation. Recent epidemiological studies emphasize the increased incidence of thromboembolic events including myocardial infarction in the HIV-infected population after the introduction of highly active antiretroviral therapy. The use of protease inhibitors in particular is implicated. A hypercoagulable state and especially thromboses are emerging as clinical issues in HIV-infected patients. Further studies are in order to more clearly delineate the pathophysiologic mechanism(s) of thromboses in HIV-infected patients.",
keywords = "Acquired immunodeficiency syndrome, Highly active antiretroviral therapy, Human immunodeficiency virus, Hypercoagulable state, Opportunistic infections, Platelet activation, Protease inhibitors, Protein S deficiency",
author = "Shen, {Yu Min P} and Frenkel, {Eugene P.}",
year = "2004",
month = "7",
doi = "10.1177/107602960401000311",
language = "English (US)",
volume = "10",
pages = "277--280",
journal = "Clinical and Applied Thrombosis/Hemostasis",
issn = "1076-0296",
publisher = "SAGE Publications Inc.",
number = "3",

}

TY - JOUR

T1 - Thrombosis and a hypercoagulable state in HIV-infected patients

AU - Shen, Yu Min P

AU - Frenkel, Eugene P.

PY - 2004/7

Y1 - 2004/7

N2 - Human immunodeficiency virus infection is an illness with protean manifestations including hematological abnormalities. Thromboembolic complications in HIV-infected patients have been described. Recent literature describes an incidence ranging from 0.26% to 7.6%; higher incidence is seen in patients with active opportunistic infections or malignancy, and in patients with the acquired immunodeficiency syndrome. A variety of potential mechanisms have been proposed to account for the observed hypercoagulability in HIV-infected patients. These include the presence of antiphospholipid- anticardiolipin antibodies, decreased activities of natural anticoagulants (especially protein S), and increased platelet activation. Recent epidemiological studies emphasize the increased incidence of thromboembolic events including myocardial infarction in the HIV-infected population after the introduction of highly active antiretroviral therapy. The use of protease inhibitors in particular is implicated. A hypercoagulable state and especially thromboses are emerging as clinical issues in HIV-infected patients. Further studies are in order to more clearly delineate the pathophysiologic mechanism(s) of thromboses in HIV-infected patients.

AB - Human immunodeficiency virus infection is an illness with protean manifestations including hematological abnormalities. Thromboembolic complications in HIV-infected patients have been described. Recent literature describes an incidence ranging from 0.26% to 7.6%; higher incidence is seen in patients with active opportunistic infections or malignancy, and in patients with the acquired immunodeficiency syndrome. A variety of potential mechanisms have been proposed to account for the observed hypercoagulability in HIV-infected patients. These include the presence of antiphospholipid- anticardiolipin antibodies, decreased activities of natural anticoagulants (especially protein S), and increased platelet activation. Recent epidemiological studies emphasize the increased incidence of thromboembolic events including myocardial infarction in the HIV-infected population after the introduction of highly active antiretroviral therapy. The use of protease inhibitors in particular is implicated. A hypercoagulable state and especially thromboses are emerging as clinical issues in HIV-infected patients. Further studies are in order to more clearly delineate the pathophysiologic mechanism(s) of thromboses in HIV-infected patients.

KW - Acquired immunodeficiency syndrome

KW - Highly active antiretroviral therapy

KW - Human immunodeficiency virus

KW - Hypercoagulable state

KW - Opportunistic infections

KW - Platelet activation

KW - Protease inhibitors

KW - Protein S deficiency

UR - http://www.scopus.com/inward/record.url?scp=3242781715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242781715&partnerID=8YFLogxK

U2 - 10.1177/107602960401000311

DO - 10.1177/107602960401000311

M3 - Article

C2 - 15247986

AN - SCOPUS:3242781715

VL - 10

SP - 277

EP - 280

JO - Clinical and Applied Thrombosis/Hemostasis

JF - Clinical and Applied Thrombosis/Hemostasis

SN - 1076-0296

IS - 3

ER -